SIO 2026 Spotlights Pain Palliation, Pressure Monitoring, Technological Innovation
Key Summary
- Autonomix Medical presents a final analysis of transvascular radiofrequency ablation neurolysis for pain mitigation at SIO 2026 in Savannah, Georgia.
- RenovoRx presents data on real-time intra-arterial pressure monitoring during TAMP (Trans-Arterial Micro-Perfusion) procedures, including a porcine-model correlation between external transducer and pressure-wire measurements.
- Exhibitor communications highlight VisAR augmented-reality navigation demonstrations (Novarad) and VR/imaging-guided ablation workflow showcases (Siemens Healthineers).
SIO 2026, the Society of Interventional Oncology Annual Scientific Meeting, is underway from February 4 to 8, 2026 at the Savannah Convention Center in Savannah, Georgia. Participating companies highlighted presentations on pancreatic cancer pain palliation and intravascular pressure measurement during trans-arterial micro-perfusion, alongside demonstrations of augmented reality and imaging workflows relevant to interventional oncology practice.
Main Announcements
SIO notes that all 2026 meeting abstracts were made public at the start of the conference (Wednesday, February 4, 2026), after which press releases were permitted for distribution.1
Autonomix Medical presented final clinical data assessing its transvascular radiofrequency (RF) ablation technique for pain relief in pancreatic adenocarcinoma. The ePoster, titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Final Analysis of Neurolysis via Transvascular Radiofrequency (RF) Ablation,” was presented by Clarke Wilkirson, PhD on Friday evening as part of the meeting’s Science and Sips programming.2
RenovoRx announced new clinical data in an abstract titled “Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro Perfusion to Optimize Drug Delivery in Solid Tumors.” TAMP (Trans-Arterial Micro-Perfusion), the company’s chemotherapy platform, carries out direct, targeted delivery to tumors with the aid of the RenovoCath. The study assessed a simplified method for capturing intra-arterial pressure during TAMP procedures and considered how these measurements, together with other variables, could inform efforts to improve targeted chemotherapy delivery to hard‑to‑treat tumors.3
On the technology side, Novarad is holding live demonstrations of VisAR, an augmented reality surgical navigation platform.4 Siemens Healthineers’ SIO 2026 page promotes hands-on experiences and product spotlights spanning ablation and CT guidance tools.5
Clinical Implications
For clinicians following SIO 2026 in Savannah, the early announcements underline 2 persistent priorities in interventional oncology: procedural precision and symptom burden.
Pain palliation remains a major unmet need in pancreatic cancer care, and Autonomix’s scheduled presentation places transvascular RF ablation neurolysis within the conference’s broader emphasis on palliative techniques (including SIO’s Palliative Pain in Cancer Patients Master Class). These emerging data complement an abstract presented at the 2026 ASCO Gastrointestinal Cancers Symposium, which describes 19 patients with severe abdominal pain from unresectable pancreatic cancer who were treated with transvascular energy. According to the authors’ conclusions, transfemoral RF ablation of the somatosensory nerve resulted in “significant pain relief.”6
Meanwhile, RenovoRx’s focus on real-time intra-arterial pressure measurement during micro-perfusion procedures highlights ongoing interest in quantifying delivery conditions during catheter-based therapies. In a porcine model, the company’s findings shows that a “simplified, external pressure transducer provides reliable and reproducible intra-arterial pressure measurements during TAMP procedures, with strong correlation to intravascular pressure wire measurements.”3 RenovoRx also stated that peak intra-arterial pressures were influenced by controllable procedural variables including catheter balloon spacing and target vessel diameter—details that may be of interest for teams considering how delivery mechanics could be standardized in future studies.3
Technological Innovations
Innovative technological demonstrations signal continued momentum around visualization and guidance. Facilitating this trend is Novarad’s VisAR, which displays patient-specific anatomy as 3D holograms to improve spatial understanding, procedural accuracy, and clinician confidence during complex image-guided interventions.4 The system currently has FDA 510(k) clearance for precision-guided intraoperative spinal surgery, and other approvals are pending.7
Siemens brings myriad devices to exemplify its advancements in this space. Featured products include the IntelliBlate, an image-guided microwave ablation system, and myAblation Guide, a tool that offers planning, placement, and assessment support for the entire microwave liver ablation process.8 Also showcased are two 3D exhibits: (1) the ARTIS icono ceiling, the most recent addition the ARTIS icono imaging line; and (2) an immersive demonstration of the SOMATOM X.cite CT Scanner and accompanying myNeedle Companion laser guidance, which incorporates Apple Vision Pro goggles and the user’s choice of Isolis cryoablation or Ximitry mircrowave ablation probes into a virtual reality experience.5
References
- Society of Interventional Oncology. Abstracts. Accessed February 6, 2026. https://www.sio-central.org/Events/Annual-Scientific-Meeting/Abstracts
- Autonomix Medical to present final analysis on pain mitigation in pancreatic cancer at SIO 2026 annual scientific meeting. News release. Autonomix Medical, Inc. January 28, 2026. Accessed February 6, 2026. https://ir.autonomix.com/autonomix-medical-to-present-final-analysis-on-pain-mitigation-in-pancreatic-cancer-at-sio-2026-annual-scientific-meeting/
- RenovoRx announces clinical data supporting the TAMP™ therapy platform will be presented at the SIO 2026 annual scientific meeting. News release. RenovoRx, Inc. February 4, 2026. Accessed February 6, 2026. https://ir.renovorx.com/news-events/press-releases/detail/146/renovorx-announces-clinical-data-supporting-the-tamp
- Novarad to attend 2026 Society of Interventional Oncology annual scientific meeting in Savannah, Georgia. News release. Business Insider. February 4, 2026. Accessed February 6, 2026. https://markets.businessinsider.com/news/stocks/novarad-to-attend-2026-society-of-interventional-oncology-annual-scientific-meeting-in-savannah-georgia-1035786496
- Siemens Healthineers. Siemens Healthineers at SIO 2026. Accessed February 6, 2026. https://www.siemens-healthineers.com/en-us/news-and-events/conferences-events-new/sio
- Schwartz R, Sabirov A, Wilkirson C. Pain mitigation in pancreatic adenocarcinoma: a long-term analysis of denervation via transvascular RF energy-based ablation. J Clin Oncol. 2026;44(2_suppl):693. doi:10.1200/JCO.2026.44.2_suppl.69
- Novarad. VisAR: immersive augmented reality surgical navigation. Accessed February 6, 2026. https://www.novarad.net/visar
- Siemens Healthineers. myAblation Guide. 2026. Accessed February 6, 2026. https://www.siemens-healthineers.com/angio/options-and-upgrades/clinical-software-applications/myablation-guide
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Vascular Disease Management or HMP Global, their employees, and affiliates.
